Remix Therapeutics
  • Our Science
    • Platform
    • Pipeline
    • REM-422
  • About Us
    • Our Story
    • Our People
    • Our Investors
    • Our Partners
  • Join Us
  • News
    • News
    • Press Releases
    • Publications
  • Clinical Trials
  • Our Science
    • Platform
    • Pipeline
    • REM-422
  • About Us
    • Our Story
    • Our People
    • Our Investors
    • Our Partners
  • Join Us
  • News
    • News
    • Press Releases
    • Publications
  • Clinical Trials
  • Contact

Month: January 2022

Is there room for a new way to drug RNA? ARCH, Foresite join Atlas, The Column Group for $81M bet

Posted on January 13, 2022February 25, 2026 by Alin

Amber Tong, Endpoints News

Read more

 

Posted in NewsLeave a Comment on Is there room for a new way to drug RNA? ARCH, Foresite join Atlas, The Column Group for $81M bet

RNA startup Remix raises $81M from Atlas, Arch Venture

Posted on January 13, 2022February 25, 2026 by Alin

Allison DeAngelis, Boston Business Journal

Read more

 

Posted in NewsLeave a Comment on RNA startup Remix raises $81M from Atlas, Arch Venture

Putting a New Spin on RNA, Remix Launches with $81 Million

Posted on January 13, 2022February 25, 2026 by Alin

Krystle Vermes, BioSpace/PharmaLive

Read more

 

Posted in NewsLeave a Comment on Putting a New Spin on RNA, Remix Launches with $81 Million

Remix: targeting RNA modulating complexes

Posted on January 13, 2022February 25, 2026 by Alin

Danielle Golovin, BioCentury

Read more

 

Posted in NewsLeave a Comment on Remix: targeting RNA modulating complexes

Recent Posts

  • Remix Therapeutics™ Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026
  • Remix Therapeutics™ Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting
  • Remix Therapeutics Granted FDA Fast Track Designation for REM-422 for the Treatment of Recurrent, Metastatic or Unresectable Adenoid Cystic Carcinoma
  • RNA-targeting small molecules: a new frontier of drug discovery
  • Remix Therapeutics Appoints Mythili Koneru, MD, PhD, as Chief Medical Officer

Recent Comments

No comments to show.

Archives

  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • November 2025
  • October 2025
  • August 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • February 2024
  • January 2024
  • December 2023
  • September 2023
  • May 2023
  • March 2023
  • January 2023
  • December 2022
  • September 2022
  • May 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • August 2021
  • March 2021
  • January 2021
  • December 2020

Categories

  • News
  • Press Release
  • Publication
Remix Therapeutics
100 Forge Road
Suite 400
Watertown, USA 02472
781-827-0901
  • Our Science
  • About Us
  • Join Us
  • News
  • Clinical Trials
  • Contact
100 Forge Road
Suite 400
Watertown, USA 02472
781-827-0901
© 2023 Remix Therapeutics, Inc. All Rights Reserved
Privacy Policy
Terms of Use